Practicable Measurement and Identification of Overbasalization
Open Access
- 1 January 2022
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 40 (1), 75-77
- https://doi.org/10.2337/cd21-0096
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Importance of Postprandial Glucose in Relation to A1C and Cardiovascular DiseaseClinical Diabetes, 2019
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic controlDiabetes, Obesity and Metabolism, 2019
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- How much is too much? Outcomes in patients using high‐dose insulin glargineInternational Journal of Clinical Practice, 2015
- A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondDrugs in Context, 2015
- Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical ConsiderationsDrugs, 2014
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin LisproDiabetes Care, 2014
- Combination therapy with GLP‐1 receptor agonists and basal insulin: a systematic review of the literatureDiabetes, Obesity and Metabolism, 2012